Akari Therapeutics, Plc

NasdaqCM AKTX

Akari Therapeutics, Plc Shareholders' Equity for the year ending December 31, 2023

Akari Therapeutics, Plc Shareholders' Equity is NA for the year ending December 31, 2023. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqCM: AKTX

Akari Therapeutics, Plc

CEO	Dr. Samir Rashmikant Patel M.D.
IPO Date	Jan. 6, 2014
Location	United Kingdom
Headquarters	75/76 Wimpole Street
Employees	6
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Key trends

Past 5 years